RUNX2 and CD4+/CD56+ hematodermic neoplasm: Furthermore, RUNX2 KD cells had significantly more Annexin V-positive cells than control vector-transduced cells (Fig. 2i), indicating that RUNX2 enhanced proliferative capacities, but also suppressed inappropriate apoptosis in BPDCN cells.